3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case.

Three Wall Street analysts now carry $500 price targets on Intuitive Surgical (ISRG), betting that robot-assisted surgery growth and the da Vinci 5 rollout can sustain the stock's momentum.

The bull case rests on two pillars. First, procedure volume: ISRG procedures are growing 15% year-over-year, the demand engine behind the analysts' targets. Second, da Vinci 5, the new platform whose rollout the three analysts cite as a driver of further upside.

The model also matters. ISRG earns recurring revenue through instruments and accessories, so each procedure feeds ongoing sales rather than a one-time system purchase. Interpretation: that structure ties revenue directly to the 15% procedure growth figure, which is why traders track utilization so closely.

The risk is valuation. ISRG trades at roughly 49 times earnings, a multiple that leaves limited room for disappointment. Interpretation: with a premium already priced in, a procedure-growth slowdown below the 15% pace could hit the shares harder than the same miss would at a cheaper multiple.

The supplied evidence includes no comparison to peers JNJ or ABT, so relative positioning rests on your own work rather than this call.